- Home
- TSVT vs CLLS Comparison
TSVT vs CLLS Comparison
Compare TSVT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- CLLS
- Stock Information
- Founded
- TSVT 2021
- CLLS 1999
- Country
- TSVT United States
- CLLS France
- Employees
- TSVT N/A
- CLLS N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- CLLS Health Care
- Exchange
- TSVT Nasdaq
- CLLS Nasdaq
- Market Cap
- TSVT 253.9M
- CLLS 240.2M
- IPO Year
- TSVT N/A
- CLLS 2007
- Fundamental
- Price
- TSVT $4.83
- CLLS $1.89
- Analyst Decision
- TSVT Buy
- CLLS Buy
- Analyst Count
- TSVT 6
- CLLS 2
- Target Price
- TSVT $10.40
- CLLS $8.00
- AVG Volume (30 Days)
- TSVT 344.9K
- CLLS 22.5K
- Earning Date
- TSVT 11-12-2024
- CLLS 11-04-2024
- Dividend Yield
- TSVT N/A
- CLLS N/A
- EPS Growth
- TSVT N/A
- CLLS N/A
- EPS
- TSVT N/A
- CLLS N/A
- Revenue
- TSVT $44,120,000.00
- CLLS $19,635,000.00
- Revenue This Year
- TSVT N/A
- CLLS $271.02
- Revenue Next Year
- TSVT $22.42
- CLLS $33.48
- P/E Ratio
- TSVT N/A
- CLLS N/A
- Revenue Growth
- TSVT N/A
- CLLS N/A
- 52 Week Low
- TSVT $1.54
- CLLS $0.96
- 52 Week High
- TSVT $6.40
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- TSVT 52.75
- CLLS 30.12
- Support Level
- TSVT $4.44
- CLLS $1.95
- Resistance Level
- TSVT $4.83
- CLLS $2.08
- Average True Range (ATR)
- TSVT 0.33
- CLLS 0.11
- MACD
- TSVT -0.00
- CLLS -0.04
- Stochastic Oscillator
- TSVT 56.86
- CLLS 0.00
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.